{"id":"NCT01958827","sponsor":"AbbVie","briefTitle":"A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease","officialTitle":"A Multicenter Open-label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Investigate Efficacy, Safety and Pharmacokinetics After Dose Escalation in Japanese Subjects With Crohn's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-09","primaryCompletion":"2015-03","completion":"2015-10","firstPosted":"2013-10-09","resultsPosted":"2016-04-12","lastUpdate":"2016-04-12"},"enrollment":28,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Crohn's Disease"],"interventions":[{"type":"BIOLOGICAL","name":"Adalimumab","otherNames":["Humira, ABT-D2E7"]}],"arms":[{"label":"Adalimumab 80 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to investigate the efficacy, safety and pharmacokinetics after dose escalation in Japanese subjects with Crohn's Disease.","primaryOutcome":{"measure":"Percentage of Participants Who Achieved Clinical Response 50 (CR50; Crohn's Disease Activity Index [CDAI] Decrease â‰¥ 50 From Week 0) at Week 8","timeFrame":"Week 8","effectByArm":[{"arm":"Adalimumab 80 mg","deltaMin":75,"sd":null}],"pValues":[]},"eligibility":{"minAge":"15 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":3},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["30221150"],"seeAlso":["http://www.rxabbvie.com"]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":28},"commonTop":["NASOPHARYNGITIS","RASH","HEADACHE","ANAEMIA","ABDOMINAL DISTENSION"]}}